Phase I randomised clinical trial of an HIV-1(CN54), clade C, trimeric envelope vaccine candidate delivered vaginally
David J Lewis, Carol A Fraser, Abdel N Mahmoud, Rebecca C Wiggins, Maria Woodrow, Alethea Cope, Chun Cai, Rafaela Giemza, Simon A Jeffs, Maria Manoussaka, Tom Cole, Martin P Cranage, Robin J Shattock, Charles J Lacey, David J Lewis, Carol A Fraser, Abdel N Mahmoud, Rebecca C Wiggins, Maria Woodrow, Alethea Cope, Chun Cai, Rafaela Giemza, Simon A Jeffs, Maria Manoussaka, Tom Cole, Martin P Cranage, Robin J Shattock, Charles J Lacey
Abstract
We conducted a phase 1 double-blind randomised controlled trial (RCT) of a HIV-1 envelope protein (CN54 gp140) candidate vaccine delivered vaginally to assess immunogenicity and safety. It was hypothesised that repeated delivery of gp140 may facilitate antigen uptake and presentation at this mucosal surface. Twenty two healthy female volunteers aged 18-45 years were entered into the trial, the first receiving open-label active product. Subsequently, 16 women were randomised to receive 9 doses of 100 µg of gp140 in 3 ml of a Carbopol 974P based gel, 5 were randomised to placebo solution in the same gel, delivered vaginally via an applicator. Participants delivered the vaccine three times a week over three weeks during one menstrual cycle, and were followed up for two further months. There were no serious adverse events, and the vaccine was well tolerated. No sustained systemic or local IgG, IgA, or T cell responses to the gp140 were detected following vaginal immunisations. Repeated vaginal immunisation with a HIV-1 envelope protein alone formulated in Carbopol gel was safe, but did not induce local or systemic immune responses in healthy women.
Trial registration: ClinicalTrials.gov NCT00637962.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
References
- Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature. 2010;464:217–223.
- Li Q, Skinner PJ, Ha SJ, Duan L, Mattila TL, et al. Visualizing antigen-specific and infected cells in situ predicts outcomes in early viral infection. Science. 2009;323:1726–1729.
- Miller CJ, Li Q, Abel K, Kim EY, Ma ZM, et al. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol. 2005;79:9217–9227.
- The GlaxoSmithKline vaccine HPV-007 study group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet. 2009;374:1975–1985.
- Ogra LP, Ogra SS. Local antibody response to poliovaccine in the human female genital tract. J Immunol. 1973;110:1307–1311.
- Klavinskis LS, Bergmeier LA, Gao L, Mitchell E, Ward RG, et al. Mucosal or targeted lymph node immunization of macaques with a particulate SIVp27 protein elicits virus-specific CTL in the genito-rectal mucosa and draining lymph nodes. J Immunol. 1996;157:2521–2527.
- Wassen L, Schon K, Holmgren J, Jertborn M, Lycke N. Local intravaginal vaccination of the female genital tract. Scand J Immunol. 1996;44:408–414.
- Kozlowski PA, Cu-Uvin S, Neutra MR, Flanigan TP. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infec Immun. 1997;65:1387–1394.
- Kozlowski PA, Williams SB, Lynch RM, Flanigan TP, Patterson RR, et al. Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J Immunol. 2002;169:566–574.
- Johannson EL, Wassen L, Holmgren J, Jertborn M, Rudin A. Nasal and vaginal vaccination have differential effects on antibody responses in vaginal and cervical secretions in humans. Infec Immun. 2001;69:7481–7486.
- Wang Y, Abel K, Lantz K, Krieg AM, McChesney MB, et al. The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques. J Virol. 2005;79:14355–14370.
- Cranage MP, Fraser CA, Stevens Z, Huting J, Chang M, et al. Repeated vaginal administration of trimeric HIV-1 clade C gp140 induces serum and mucosal antibody responses. Mucosal Immunol. 2010;3:57–68.
- Curran RM, Donnelly L, Morrow RJ, Fraser C, Andrews G, et al. Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses. Vaccine. 2009;27:6791–6798.
- Currier JR, Kuta EG, Turk E, Earhart LB, Loomis-Price L, et al. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods. 2002;260:157–172.
- Pialoux G, Hocini H, Perusat S, Silberman B, Salmon-Ceron D, et al. Phase 1 study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: the ANRS VAC14 study. Vaccine. 2008;26:2657–2666.
- Barberini F, Correr S, De Santis F, Motta PM. The epithelium of the rabbit vagina: a microtopographical study by light, transmission and scanning electron microscopy. Arch Histol Cytol. 1991;54:365–378.
- Cranage MP, Fraser CA, Cope A, McKay PF, Seaman MS, et al. Antibody responses after intravaginal immunisation with trimeric HIV-1CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation. Vaccine. 2011;29:1421–1430.
- Krashias G, Simon A-K, Wegmann F, Kok WL, Ho LP, et al. Potent adaptive immune responses induced against HIV-1 gp140 and influenza virus HA by a polyanionic carbomer. 2010;28:2482–2489.
- Raux M, Finkielsztejn L, Salmon-Ceron D, Bouchez H, Excler JL, et al. Comparison of the distribution of IgG and IgA antibodies in serum and various mucosal fluids of HIV type1-infected subjects. AIDS Res Hum Retroviruses. 1999;15:1365–1376.
- Mestecky J, Moldoveanu Z, Smith PD, Hel Z, Alexander RC. Mucosal immunology of the genital and gastrointestinal tracts and HIV-1 infection. J Reprod Immunol. 2009;83:196–200.
- Mestecky J, Wright P, Lopalco L, Staats HF, Kozlowski PA, et al. Scarcity or absence of humoral immune responses in the plasma or cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women. AIDS Res Hum Retroviruses. 2011;27:469–486.
- Tudor D, Derrien M, Diomede L, Drillet AS, Houimel M, et al. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis. Mucosal Immunology. 2009;2:412–426.
- Safaeian M, Kemp T, Falk RT, Rodriguez AC, Hildesheim A, et al. Determinants and correlation of systemic and cervical concentrations of total IgA and IgG. Cancer Epidemiol Biomarkers Prev. 2009;18:2672–2676.
- Kaul R, Thottingal P, Kimani J, Kiama P, Waigwa CW, et al. Quantitative ex vivo analysis of functional virus-specific CD8 T lymphocytes in the blood and genital tract of HIV-infected women. AIDS. 2003;17:1139–1144.
- Gumbi PP, Nkwanyana NN, Bere A, Burgers WA, Gray CM, et al. Impact of mucosal inflammation on cervical human immunodeficiency virus (HIV-1)-specific CD8 T-cell responses in the female genital tract during chronic HIV infection. J Virol. 2008;82:8529–8536.
- Bere A, Denny L, Burgers WA, Passmore J-A. Polyclonal expansion of cervical cytobrush-derived T cells to investigate HIV-specific responses in the female genital tract. Immunology. 2010;133:23–33.
- Boskey ER, Moench TR, Hees PS, Cone RA. A self-sampling method to obtain large volumes of undiluted cervicovaginal secretions. Sex Transm Dis. 2003;30:107–109.
Source: PubMed